211 related articles for article (PubMed ID: 31980928)
21. Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
Rossini M; Viapiana O; Zanotti R; Tripi G; Perbellini O; Idolazzi L; Bonifacio M; Adami S; Gatti D
Calcif Tissue Int; 2015 May; 96(5):410-6. PubMed ID: 25694360
[TBL] [Abstract][Full Text] [Related]
22. Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis.
van der Veer E; Arends S; van der Hoek S; Versluijs JB; de Monchy JGR; Oude Elberink JNG; van Doormaal JJ
J Allergy Clin Immunol; 2014 Dec; 134(6):1413-1421. PubMed ID: 24985401
[TBL] [Abstract][Full Text] [Related]
23. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.
Trizuljak J; Sperr WR; Nekvindová L; Elberink HO; Gleixner KV; Gorska A; Lange M; Hartmann K; Illerhaus A; Bonifacio M; Perkins C; Elena C; Malcovati L; Fortina AB; Shoumariyeh K; Jawhar M; Zanotti R; Bonadonna P; Caroppo F; Zink A; Triggiani M; Parente R; von Bubnoff N; Yavuz AS; Hägglund H; Mattsson M; Panse J; Jäkel N; Kilbertus A; Hermine O; Arock M; Fuchs D; Sabato V; Brockow K; Bretterklieber A; Niedoszytko M; van Anrooij B; Reiter A; Gotlib J; Kluin-Nelemans HC; Mayer J; Doubek M; Valent P
Allergy; 2020 Aug; 75(8):1927-1938. PubMed ID: 32108361
[TBL] [Abstract][Full Text] [Related]
24. Routine abdominal ultrasonography has limited value in the care for patients with indolent systemic mastocytosis.
de Mol CL; Hermans MAW; Gerth van Wijk R; van Hagen PM; van Daele PLA
Hematology; 2017 Oct; 22(9):544-547. PubMed ID: 28486845
[TBL] [Abstract][Full Text] [Related]
25. Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.
Marton I; Krenács L; Bagdi E; Bakos A; Demeter J; Borbényi Z
Pathol Oncol Res; 2016 Apr; 22(2):293-9. PubMed ID: 26545382
[TBL] [Abstract][Full Text] [Related]
26. Endocrine manifestations of systemic mastocytosis in bone.
Greene LW; Asadipooya K; Corradi PF; Akin C
Rev Endocr Metab Disord; 2016 Sep; 17(3):419-431. PubMed ID: 27239674
[TBL] [Abstract][Full Text] [Related]
27. Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series.
Orsolini G; Gavioli I; Tripi G; Viapiana O; Gatti D; Idolazzi L; Zanotti R; Rossini M
Calcif Tissue Int; 2017 Jun; 100(6):595-598. PubMed ID: 28229176
[TBL] [Abstract][Full Text] [Related]
28. Novel approaches to treating advanced systemic mastocytosis.
Gilreath JA; Tchertanov L; Deininger MW
Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
[TBL] [Abstract][Full Text] [Related]
29. Low risk of contrast media-induced hypersensitivity reactions in all subtypes of systemic mastocytosis.
Schwaab J; Brockow K; Riffel P; Lübke J; Naumann N; Jawhar M; Reiter L; Fabarius A; Metzgeroth G; Schoenberg SO; Hofmann WK; Reiter A; Riffel J
Ann Allergy Asthma Immunol; 2022 Mar; 128(3):314-318. PubMed ID: 34637924
[TBL] [Abstract][Full Text] [Related]
30. Bone mastocytosis. A report of nine cases with a bone histomorphometric study.
de Gennes C; Kuntz D; de Vernejoul MC
Clin Orthop Relat Res; 1992 Jun; (279):281-91. PubMed ID: 1600667
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry.
Niedoszytko M; Gorska A; Brockow K; Bonadonna P; Lange M; Kluin-Nelemans H; Oude-Elberink H; Sabato V; Shoumariyeh K; von Bubnoff D; Müller S; Illerhaus A; Doubek M; Angelova-Fischer I; Hermine O; Arock M; Elena C; Malcovati L; Yavuz AS; Schug TD; Fortina AB; Judit V; Gotlib J; Panse J; Vucinic V; Reiter A; Schwaab J; Triggiani M; Mattsson M; Breynaert C; Romantowski J; Zanotti R; Olivieri E; Zink A; van de Ven A; Stefan A; Barete S; Caroppo F; Perkins C; Kennedy V; Christen D; Jawhar M; Luebke J; Parente R; Levedahl K; Hadzijusufovic E; Hartmann K; Nedoszytko B; Sperr WR; Valent P
Allergy; 2024 Apr; ():. PubMed ID: 38651829
[TBL] [Abstract][Full Text] [Related]
32. Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis.
Rama TA; Henriques AF; Matito A; Jara-Acevedo M; Caldas C; Mayado A; Muñoz-González JI; Moreira A; Cavaleiro-Rufo J; García-Montero A; Órfão A; Sanchez-Muñoz L; Álvarez-Twose I
J Allergy Clin Immunol Pract; 2023 May; 11(5):1536-1547. PubMed ID: 36801493
[TBL] [Abstract][Full Text] [Related]
33. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients.
Theoharides TC; Boucher W; Spear K
Int Arch Allergy Immunol; 2002 Aug; 128(4):344-50. PubMed ID: 12218373
[TBL] [Abstract][Full Text] [Related]
34. Systemic mastocytosis and bone involvement in a cohort of 75 patients.
Barete S; Assous N; de Gennes C; Grandpeix C; Feger F; Palmerini F; Dubreuil P; Arock M; Roux C; Launay JM; Fraitag S; Canioni D; Billemont B; Suarez F; Lanternier F; Lortholary O; Hermine O; Francès C
Ann Rheum Dis; 2010 Oct; 69(10):1838-41. PubMed ID: 20570833
[TBL] [Abstract][Full Text] [Related]
35. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
36. Bone complications of mastocytosis: a link between clinical and biological characteristics.
Guillaume N; Desoutter J; Chandesris O; Merlusca L; Henry I; Georgin-Lavialle S; Barete S; Hirsch I; Bouredji D; Royer B; Gruson B; Lok C; Sevestre H; Mentaverri R; Brazier M; Meynier J; Hermine O; Marolleau JP; Kamel S; Damaj G
Am J Med; 2013 Jan; 126(1):75.e1-7. PubMed ID: 23200108
[TBL] [Abstract][Full Text] [Related]
37. Bone involvement and osteoporosis in mastocytosis.
Rossini M; Zanotti R; Viapiana O; Tripi G; Orsolini G; Idolazzi L; Bonadonna P; Schena D; Escribano L; Adami S; Gatti D
Immunol Allergy Clin North Am; 2014 May; 34(2):383-96. PubMed ID: 24745681
[TBL] [Abstract][Full Text] [Related]
38. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.
Gotlib J; Kluin-Nelemans HC; Akin C; Hartmann K; Valent P; Reiter A
Expert Opin Biol Ther; 2021 Apr; 21(4):487-498. PubMed ID: 33063554
[TBL] [Abstract][Full Text] [Related]
39. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
40. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
